List view / Grid view

Baricitinib (Olumiant)

Filter the results

 

news

EC approves Eli Lilly’s rheumatoid arthritis drug

16 February 2017 | By Niamh Marriott, Digital Editor

The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).

news

FDA extends review period for Eli Lilly’s rheumatoid arthritis drug

16 January 2017 | By Niamh Marriott, Digital Editor

The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly and Incyte’s new drug application for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA).